Clasificación en acciones
#40642
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Precio por acción
$0.00323826
Última sincronización: 2026-08-12
Capitalización bursátil
$104.81K
Comercio Purple Biotech Ltd. (PPBT)
Margen Operativo de Purple Biotech Ltd. (PPBT)
Margen Operativo al 2026 TTM: 0.00%
Según los informes financieros más recientes y el precio de las acciones de Purple Biotech Ltd., el margen operativo actual (TTM) es 0.00%. Al final de 2026, el margen operativo era 0.00%.
Historial de Margen Operativo de Purple Biotech Ltd. desde 2026 hasta 2026
Margen Operativo al final de cada año
| Año |
Margen Operativo |
Cambiar |
|
Not enough data for the provided dates. |
Margen Operativo de empresas similares o competidoras
| Empresa |
Margen Operativo |
Diferencia de Margen Operativo |
País |
|
|
38.97% |
-
|
US
|
|
|
28.81% |
-
|
NL
|
|
|
0.00% |
-
|
CH
|
|
|
0.00% |
-
|
KR
|
|
|
31.23% |
-
|
BE
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.
